ArticleFrontiers in human neuroscience2026
Target-specific modulation of cortical narrowband gamma by basal ganglia nuclei: a case report.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Narrow-band gamma (NBG) is an oscillatory activity in the gamma band (60-90 Hz) that has been observed in the subthalamic nucleus (STN), the motor cortex, and, more recently, the globus pallidus internus (GPi) of Parkinson's disease (PD) patients, often in the on-medication state. Therapeutic DBS has been shown to modulate NBG, often entraining cortical and subcortical NBG to half the stimulation frequency, often referred to as finely tuned gamma (FTG). However, the differential effect of STN, GPi, and GPe DBS on cortical NBG has never been explored in the same patient. Method: We report a case of a 54-year-old female patient with early-onset PD harboring Result: At baseline, the primary motor cortex (M1) exhibited prominent NBG activity at 68 Hz. Both STN and GPi DBS induced similar effects, leading to NBG suppression. These neurophysiological changes were accompanied by modest clinical improvements in rigidity and dystonia. In contrast, GPe DBS did not suppress NBG and was not associated with any clinical benefit. Discussion: Our results show that therapeutic and nontherapeutic basal ganglia stimulation differentially modulated M1 NBG, supporting the potential utility of this activity as a biomarker for therapeutic stimulation. The absence of entrainment during STN and GPi stimulation might be due to high frequency (180 Hz) exceeding the range of cortical synchronization and FTG emergence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.